2022
DOI: 10.3390/joitmc8020063
|View full text |Cite
|
Sign up to set email alerts
|

A New Digital Value Chain Model with PLC in Biopharmaceutical Industry: The Implication for Open Innovation

Abstract: The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate with the product-life-cycle perspective to better explain the drug development process changes and how the digital transformation could be implemented at each stage of the drug development process. We suggest a new framework to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 16 publications
(13 citation statements)
references
References 35 publications
0
6
0
Order By: Relevance
“…The COVID-19 pandemic has dramatically increased the adaptability of digital technologies in healthcare. The use of digital technologies in the pharmaceutical industry, known as Pharma 4.0, aims to gain a competitive advantage by simplifying and increasing efficiency in each of the pharmaceutical value chains (Arden et al 2021;Kim et al 2022). However, research on how to use this new technology to determine performanceenhancing benefits remains limited.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The COVID-19 pandemic has dramatically increased the adaptability of digital technologies in healthcare. The use of digital technologies in the pharmaceutical industry, known as Pharma 4.0, aims to gain a competitive advantage by simplifying and increasing efficiency in each of the pharmaceutical value chains (Arden et al 2021;Kim et al 2022). However, research on how to use this new technology to determine performanceenhancing benefits remains limited.…”
Section: Discussionmentioning
confidence: 99%
“…Pharmaceutical and healthcare businesses are among those rapidly accelerating digital transformation (Arden et al 2022;Clark et al 2020). It is believed that digitizing Pharma technology throughout the value chain will boost competitive advantage, productivity, efficiency, product marketing, and industrial expansion (e.g., Kim et al 2022;Kumar et al 2020;Reinhardt et al 2020;Saha et al 2022).…”
Section: Introductionmentioning
confidence: 99%
“…A comprehensive assessment of the internal CSR system encourages the need to simultaneously take into consideration heterogeneous characteristics that cannot be compared with each other both in units of measurement and in absolute values. For example, the return on capital and the coefficient of constancy of personnel differ by several orders of magnitude in absolute value and at the same time turn out to be incomparable in economic content [8,14].…”
Section: Development Of a Scientific And Methodological Approach To D...mentioning
confidence: 99%
“…Works [7,8] also consider the levels of maturity of the enterprise but in the context of management and technological maturity, the concept of ranking the enterprise is formed. The disadvantage of the work is that the level of CSR is not taken into consideration and the digitalization of business is not considered as one of the key elements of the development of a modern enterprise.…”
Section: Literature Review and Problem Statementmentioning
confidence: 99%
See 1 more Smart Citation